Sophia Genetics (SOPH) Stock
Technology sector company. Here's the price, business snapshot, and what's worth knowing about Sophia Genetics in September 2026.
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying SOPH's stock, with a target price of $8.8 indicating significant growth potential.
Financial Health
SOPHIA GENETICS is performing well with solid revenue, profit margins, and cash flow generation.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
